Molecular profiling is critical for identifying and characterizing the unique somatic mutations that accrue in cancer cells. Comprehensive tumor and blood profiles can help to identify biomarkers that are prognostic or predictive, relevant in clinical trials, or cited in recent clinical studies.
Next-generation sequencing (NGS) is becoming more widely adopted as a valuable method for somatic mutation analysis in cancer. NGS offers high sensitivity, ease of use, and accurate data quality for identifying even rare mutations successfully. These advantages are driving increased adoption of NGS in clinical cancer research.
Targeted sequencing of solid tumors can identify somatic mutations associated with cancer, even among highly heterogeneous tissues. Comprehensively assess all genes associated with solid tumors, including lung, colon, breast, melanoma, gastric, and ovarian cancers.Learn More
Liquid tumors, such as myeloid and lymphoid malignancies, often carry somatic mutations that are distinct from solid tumors. Molecular profiling of hematological cancers assesses all relevant genes and detects all classes of genetic mutations at one time.Learn More
Although all cancers are unique, many share common driver mutations. Pan-cancer profiling detects relevant somatic mutations across all types of cancers, regardless of origin.Learn More
Illumina sequencing products facilitate clinical cancer research by providing expert-defined gene content, accurate data, and simple analysis and reporting options.Learn More
The Illumina DRAGEN (Dynamic Read Analysis for GENomics) Bio-IT Platform provides accurate, ultra-rapid secondary analysis of NGS data. A variety of analysis apps are available, including the DRAGEN Somatic Pipeline. This app includes tumor-only and tumor–normal modes for detecting somatic variants in whole-genome and whole-exome sequencing samples.View Product